A General Molecular Strategy for Attenuation of Human Pathogenic Arenaviruses
人类致病性沙粒病毒减毒的通用分子策略
基本信息
- 批准号:9112491
- 负责人:
- 金额:$ 28.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-05 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAfricaAnimal ModelAntigensAreaArenavirusAttenuatedAttenuated Live Virus VaccineCaviaCell LineCellsClinicalClinical TrialsCompetenceConsensus SequenceCultured CellsDevelopmentDideoxy Chain Termination DNA SequencingDiseaseEngineeringEpidemiologic StudiesExhibitsFutureGeneticGenomeGoalsGrowthHeterophile AntigensHumanImmune responseImmunityIndividualInfectionInterferonsKnowledgeLabelLassa FeverLassa virusLicensingLujo virusLymphocytic choriomeningitis virusMediatingModelingMolecularMorbidity - disease rateMusMutationOld World ArenavirusesPhenotypePopulationProductionPropertyProtocols documentationPublic HealthRecombinantsResourcesRibavirinSerial PassageSouth AfricaSymptomsTestingTravelVaccinesViralViral Hemorrhagic FeversVirulenceVirusVirus Diseasesattenuationbasebiodefenseclinically significantcombatdesigngenetic approachin vivointerestmetropolitanmortalitymouse modelneglectnovelnovel strategiespathogenpublic health relevancepyrosequencingresponsereverse genetics
项目摘要
DESCRIPTION (provided by applicant): Several arenaviruses cause hemorrhagic fever (HF) disease in humans and pose a serious public health problem in their endemic regions. Thus, the Old World arenavirus (OWA) Lassa (LASV) infects several hundred thousand individuals yearly in West Africa resulting in a high number of Lassa fever (LF) cases associated with high morbidity and mortality. Moreover, evidence indicates that the worldwide-distributed OWA LCMV is a neglected clinically important human pathogen. In addition, several arenaviruses including LASV and LCMV pose a credible biodefense threat. Existing anti-arenaviral therapy is limited to an off-label use of ribavirin that is only partially effective, and there are no FDA-licensed, or currently in clinical trials, arenavirus vaccines. However, the MOPV/LASV reassortant (ML29) is a candidate live-attenuated vaccine (L-AttV) for LASV that has shown promising results in animal models. Nevertheless, as with many other traditional L-AttV, the mechanism of ML29 attenuation remains unknown, which raises concerns about the phenotypic stability of ML29 in response to additional mutations. The central goal of this application is to test the hypothesis that we can convert a pathogenic OWA into an attenuated form with features of L-AttV via replacement of its L IGR by a genetically defined synthetic S-like IGR (Ssyn). Our hypothesis is supported by our recent following findings: 1) We could rescued rLCMV(IGR/S-S) with the same S-IGR in both S and L genome segments, and found that it was highly attenuated in vivo. 2) Mice immunized with rLCMV(IGR/S-S) were protected against a lethal challenge with wild type (WT) LCMV. 3) We have obtained evidence that a high degree of sequence plasticity within the S IGR is compatible with virus viability, which supports the feasibility of engineering recombinant arenaviruses with a synthetic S IGR (Ssyn) in the L segment as a general molecular strategy for arenavirus attenuation. To test our hypothesis we propose to complete the following specific aims: Aim 1. Characterize rLCMV (IGR/S-Ssyn): We have rescued rLCMV(IGR/S-Ssyn) where a synthetic S IGR (Ssyn) substituted for the L-IGR. We will characterize rLCMV(IGR/S-Ssyn) in cultured cells and using the mouse model of LCMV infection test the hypothesis that rLCMV(IGR/S-Syn) displays key features for L-AttV. Aim 2: Generate and characterize rLASV(IGR/S-Ssyn): We will generate rLASV(IGR/S-Ssyn) and test the hypothesis that it is attenuated in vivo but able to induce protective immunity against a letha challenge with WT LASV in a well-established guinea pig model of LASV infection. Aim 3. Examine the stability of rLCMV(IGR/S-Ssyn): We will test the hypothesis that rLCMV(IGR/S-Ssyn) is genetically stable during multiplication under different growth conditions. The successful completion of this application will uncover a general molecular strategy for arenavirus attenuation that can facilitate a novel strategy to develop L-AttV to combat human pathogenic arenaviruses.
描述(由申请方提供):几种沙粒病毒在人类中引起出血热(HF)疾病,并在其流行地区造成严重的公共卫生问题。因此,旧世界沙粒病毒(OWA)拉沙(LASV)每年在西非感染数十万个体,导致与高发病率和死亡率相关的大量拉沙热(LF)病例。此外,有证据表明,世界范围内分布的OWA LCMV是一种被忽视的临床重要的人类病原体。此外,包括LASV和LCMV在内的几种沙粒病毒构成了可信的生物防御威胁。现有的抗沙粒病毒疗法仅限于标签外使用病毒唑,仅部分有效,并且没有FDA许可的或目前处于临床试验中的沙粒病毒疫苗。然而,MOPV/LASV抑制剂(ML 29)是LASV的候选减毒活疫苗(L-AttV),其在动物模型中显示出有希望的结果。然而,与许多其他传统的L-AttV一样,ML 29减毒的机制仍然未知,这引起了对ML 29响应于额外突变的表型稳定性的担忧。本申请的中心目标是检验我们可以通过用遗传上定义的合成S样IGR(Ssyn)替换其L IGR将致病性OWA转化为具有L-AttV特征的减毒形式的假设。我们的假设得到了以下结果的支持:1)我们可以拯救S和L基因组片段具有相同S-IGR的rLCMV(IGR/S-S),并且发现它在体内是高度减毒的。2)用rLCMV(IGR/S-S)免疫的小鼠被保护免受野生型(WT)LCMV的致死攻击。3)我们已经获得证据表明,S IGR内的高度序列可塑性与病毒活力相容,这支持了在L区段中用合成的S IGR(Ssyn)工程化重组沙粒病毒作为沙粒病毒减毒的一般分子策略的可行性。为了验证我们的假设,我们建议完成以下具体目标:目标1。表征rLCMV(IGR/S-Ssyn):我们已经拯救了rLCMV(IGR/S-Ssyn),其中合成的S IGR(Ssyn)取代了L-IGR。我们将在培养的细胞中表征rLCMV(IGR/S-Ssyn),并使用LCMV感染的小鼠模型测试rLCMV(IGR/S-Syn)显示L-AttV的关键特征的假设。目标二:生成和表征rLASV(IGR/S-Ssyn):我们将生成rLASV(IGR/S-Ssyn)并检验以下假设:其在体内减毒,但能够在完善的LASV感染豚鼠模型中诱导针对WT LASV致死性攻毒的保护性免疫。目标3。检查rLCMV(IGR/S-Ssyn)的稳定性:我们将检验rLCMV(IGR/S-Ssyn)在不同生长条件下增殖期间遗传稳定的假设。该申请的成功完成将揭示沙粒病毒减毒的一般分子策略,其可以促进开发L-AttV以对抗人类致病性沙粒病毒的新策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Juan C. de la Torre其他文献
Reverse-genetic approaches to the study of Borna disease virus
伯尔尼病病毒研究的反向遗传学方法
- DOI:
10.1038/nrmicro1489 - 发表时间:
2006-09-11 - 期刊:
- 影响因子:103.300
- 作者:
Juan C. de la Torre - 通讯作者:
Juan C. de la Torre
Establishment of recombinant ML29 platform for the generation of polyvalent live-attenuated vaccines against Lassa virus and other infectious agents
建立重组 ML29 平台,用于生产针对拉沙病毒和其他传染原的多价减毒活疫苗
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Masaharu Iwasaki;Beatrice Cubitt;Daisuke Motooka;Dylan M. Johnson;Igor S. Lukashevich;Juan C. de la Torre - 通讯作者:
Juan C. de la Torre
Juan C. de la Torre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Juan C. de la Torre', 18)}}的其他基金
Improving The Scripps Research Institute BSL3 Capabilities to Combat Viruses of Pandemic Concern
提高斯克里普斯研究所 BSL3 对抗流行病病毒的能力
- 批准号:
10611798 - 财政年份:2022
- 资助金额:
$ 28.88万 - 项目类别:
Designing mammarenavirus live vaccines with unbreachable attenuation
设计具有不可破坏的减毒效果的乳腺病毒活疫苗
- 批准号:
10664016 - 财政年份:2022
- 资助金额:
$ 28.88万 - 项目类别:
Designing mammarenavirus live vaccines with unbreachable attenuation
设计具有不可破坏的减毒效果的乳腺病毒活疫苗
- 批准号:
10535058 - 财政年份:2022
- 资助金额:
$ 28.88万 - 项目类别:
Development and validation of antivirals against hemorrhagic fever viruses of pandemic concern
针对大流行病的出血热病毒的抗病毒药物的开发和验证
- 批准号:
10514329 - 财政年份:2022
- 资助金额:
$ 28.88万 - 项目类别:
Modulation of Lassa Virus vRNP Activity By Host Cell Factors
宿主细胞因子对拉沙病毒 vRNP 活性的调节
- 批准号:
9321544 - 财政年份:2017
- 资助金额:
$ 28.88万 - 项目类别:
A General Molecular Strategy for Attenuation of Human Pathogenic Arenaviruses
人类致病性沙粒病毒减毒的通用分子策略
- 批准号:
9217579 - 财政年份:2016
- 资助金额:
$ 28.88万 - 项目类别:
Activity-Based Protein Profiling of Arenavirus-Host Interactions
基于活性的沙粒病毒-宿主相互作用的蛋白质分析
- 批准号:
8970028 - 财政年份:2015
- 资助金额:
$ 28.88万 - 项目类别:
Profiling Serine Hydrolase Activity At The Virus-Host Interface
病毒-宿主界面丝氨酸水解酶活性分析
- 批准号:
8869489 - 财政年份:2015
- 资助金额:
$ 28.88万 - 项目类别:
Profiling Serine Hydrolase Activity At The Virus-Host Interface
病毒-宿主界面丝氨酸水解酶活性分析
- 批准号:
9085225 - 财政年份:2015
- 资助金额:
$ 28.88万 - 项目类别:
Immune cell dynamics during central nervous system viral infection
中枢神经系统病毒感染期间的免疫细胞动力学
- 批准号:
7581118 - 财政年份:2009
- 资助金额:
$ 28.88万 - 项目类别:
相似海外基金
Multi-component interventions to reducing unhealthy diets and physical inactivity among adolescents and youth in sub-Saharan Africa (Generation H)
采取多方干预措施减少撒哈拉以南非洲青少年的不健康饮食和缺乏身体活动(H 代)
- 批准号:
10106976 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
EU-Funded
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
- 批准号:
ES/Y00860X/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Fellowship
Decolonization, Appropriation and the Materials of Literature in Africa and its Diaspora
非洲及其侨民的非殖民化、挪用和文学材料
- 批准号:
EP/Y024516/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Research Grant
Exploring "Actionable Information" for Learning Improvement in Rural East Africa: A Positive Deviance Approach
探索东非农村地区学习改进的“可行信息”:积极偏差方法
- 批准号:
24K00390 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
ePowerCart - Affordable Mobile Clean Energy for Remote Communities in Rural Sub-Saharan Africa and India
ePowerCart - 为撒哈拉以南非洲和印度农村偏远社区提供经济实惠的移动清洁能源
- 批准号:
10076185 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Collaborative R&D
Protecting Women from Economic shocks to fight HIV in Africa (POWER)
保护非洲妇女免受经济冲击,抗击艾滋病毒 (POWER)
- 批准号:
MR/Y003837/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Fellowship
Tackling antimicrobial resistance across dentistry in Sub-Saharan Africa.
解决撒哈拉以南非洲牙科领域的抗菌素耐药性问题。
- 批准号:
MR/Y019695/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Research Grant
Water stressed cities: individual choice, access to water and pathways to resilience in sub-Saharan Africa
缺水城市:撒哈拉以南非洲地区的个人选择、水资源获取和恢复力途径
- 批准号:
MR/X022943/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Fellowship
The Open fracture National Evaluation (ONE) Study - South Africa: Improving outcomes in the care of open fractures in low resource settings
开放性骨折国家评估 (ONE) 研究 - 南非:改善资源匮乏地区开放性骨折的护理效果
- 批准号:
MR/Y00955X/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Fellowship
Recognising & supporting informal mhealth in Africa through grassroots interventions (REIMAGINE)
认识
- 批准号:
MR/Y015614/1 - 财政年份:2024
- 资助金额:
$ 28.88万 - 项目类别:
Research Grant